N2N Technologies open offer: IDC backs ₹4.30 bid

IDC recommends shareholders accept the offer

N2N Technologies Ltd said its Independent Directors Committee (IDC) has officially recommended that shareholders accept the open offer made by Harmony Remedies India Private Limited. The recommendation follows the IDC’s review of the proposed acquisition and the offer terms. The committee said the offer price of ₹4.30 per equity share is fair. It also said the offer is compliant with SEBI regulations.

For minority shareholders, the IDC’s view matters because it provides an independent assessment of the pricing and process. The recommendation comes at a time when investors have limited market-based cues for valuation due to the company’s trading status on the exchange. The open offer is positioned as a route for shareholders to tender shares at a known cash price, subject to the offer’s terms and acceptance.

What Harmony Remedies is offering to buy

Under the open offer, Harmony Remedies India Private Limited aims to acquire up to 12,91,228 equity shares of N2N Technologies. The offer size represents 40% of N2N Technologies’ expanded voting share capital. The offer price is fixed at ₹4.30 per share.

The total consideration if the offer is fully accepted is stated as ₹55.52 lakh. Separately, the escrow amount disclosed is ₹56.00 lakh, placed with Kotak Mahindra Bank. The acquirer is described as primarily a pharmaceutical business, while N2N Technologies operates in the IT services sector.

Timeline and key parties named in the process

The tendering period for the open offer is stated to run from December 18, 2025, to January 1, 2026. The expected closing date mentioned for the transaction is January 1, 2026. A BSE filing referenced a “Detailed Public Announcement” received from Inga Ventures Private Limited, described as manager to the offer, dated November 7, 2025.

The open offer has also been described as being made by Harmony Remedies India Pvt Ltd along with persons acting in concert (PACs) named as Firoze Nariman Kapadia and Aditi Vipin Parikh. MUFG Intime India Private Limited is named as registrar to the offer in the transaction description.

Trading suspension on BSE remains the central complication

A major issue for shareholders is that N2N Technologies’ shares are currently suspended from trading on the Bombay Stock Exchange (BSE). The suspension is linked to past non-compliance with listing requirements. The cited issues include delays in filing financial results and not appointing a secretarial auditor.

The suspension affects investors in two direct ways. First, it makes price discovery difficult, because shareholders cannot reliably observe an active market price for the stock in normal trading. Second, it reduces liquidity, leaving shareholders with limited options to exit, whether through the open offer or later when trading resumes.

Company says it has applied for revocation of suspension

N2N Technologies has disclosed that it cleared its outstanding annual listing fees with BSE and submitted an application for revocation of the trading suspension. The company said it would provide further updates as developments occur. This step is positioned as necessary before normal trading can resume, and the next stated step is awaiting BSE approval.

The company also disclosed information about promoter Rahul Shah’s legal proceedings in Illinois courts, stating that these matters are unrelated to company operations. Alongside these updates, the open offer for a 40% stake remains active.

Company background and listing identifiers

N2N Technologies, previously known as Fervent Technologies, operates in the IT services sector. The stock is associated with BSE scrip code 512279 and ISIN INE043F01011. The information provided also notes that N2N Technologies is not listed on NSE.

While the company is identified as an IT services player in the open offer context, investors are also dealing with the practical impact of the trading halt. That gap between corporate disclosures and day-to-day trading access is a core feature of this situation.

What shareholders must weigh before tendering

With the IDC’s endorsement, shareholders have a clearer recommendation to consider when deciding whether to tender their shares. If the open offer is successful, it could alter the company’s ownership structure. But the decision is complicated by the suspended stock, which limits the ability to benchmark the ₹4.30 offer against an observable market value.

The primary risk highlighted is the continued trading suspension, which hinders both price discovery and liquidity. Investors will be monitoring shareholder decisions on tendering, the success rate of Harmony Remedies’ bid, and any announcements on lifting the BSE trading suspension. The offer period’s closing date is also a key point to track.

Key facts table: offer terms and suspension status

Key dates and disclosures

Market impact: liquidity and valuation constraints

Because the shares are suspended on BSE, investors cannot rely on active trading to test demand, compare bids, or assess an evolving price level. That increases the importance of the disclosed offer price and the IDC’s fairness assessment, while also increasing uncertainty for investors who prefer market-based valuation.

The suspension also affects liquidity, since the ability to sell shares outside corporate actions is constrained. The company’s statement that it has paid outstanding annual listing fees and applied for revocation is relevant in this context, but the next step is explicitly dependent on BSE approval.

Analysis: why this open offer is closely watched

This situation combines a standard open offer framework with the added complexity of a trading suspension. The offer is clearly defined by share quantity, percentage of expanded voting share capital, tender dates, and escrow funding. At the same time, the inability to trade normally makes shareholder decision-making more dependent on disclosures, process steps, and regulatory timelines.

The named institutions and roles also matter for process clarity: Inga Ventures Pvt Ltd is referenced as manager to the offer, and MUFG Intime India Private Limited is identified as registrar. For shareholders, the most trackable next developments are the offer closure date, disclosures on acceptance levels, and any formal update from BSE on the revocation application.

Conclusion

N2N Technologies’ IDC has recommended shareholders accept Harmony Remedies India Private Limited’s open offer at ₹4.30 per share for up to 12,91,228 shares, representing 40% of expanded voting share capital. The decision for investors remains shaped by the ongoing BSE trading suspension, which restricts price discovery and liquidity. The next confirmed milestones to watch are the end of the tendering period on January 1, 2026 and updates on BSE’s decision on revoking the trading suspension.